There may also be individual differences, as seen in the rapamycin study (7/14 patients with inhibition of tumor cell proliferation) where these differences were found to be host-related (cell type/tissue specific sequestration) rather than cell intrinsic (mutation of drug target), as seen by successful rapamycin induced mTOR inhibition of ex vivo tumor cultures [16]. Here, MTOR is linked to neoplasm.